National Clinical Homecare Association - NHCA

What next after the House of Lords Review? Quantifying the value of clinical homecare

1

Chris Carver – NCHA Board member / HealthNet Homecare Deputy Chief Executive

NCHA Board Member

2

Agenda

Current status of the House of Lords inquiry and what's next?

Introduce you to a new report which aims to provide a greater understanding of the Homecare Market Sector …

- Background to the Report – Why NCHA commissioned this independent report
- How this fits in with the House of Lords Public inquiry
- What is the Value of the Report
- What Methodology was used
- Quantified benefits of clinical homecare

3

House of Lords update

4

Inquiry Timeline



5

House of Lords recommendations

- Clinical homecare "should be a key part of future planning and resourcing"
- Senior ownership within the NHS
- Improved transparency
- Central resourcing of homecare procurement and management
- Review regulatory framework

6

What Next?

- NHSE desktop review to be published
- Scottish Homecare review to be published
- GPhC inspecting homecare pharmacies
- 4th July and beyond

7

Best Kept Secret introduction and background

8

This report seeks to **improve understanding of Clinical Homecare and the value it brings to patients, the NHS and society at large.** Work on this report started before the recent House of Lords inquiry was commissioned. The report acknowledges the inquiry, the recommendations and the government's response. **It is hoped that this report will provide useful information that contributes to this important conversation.**



9

Introduction to Report Content

Aim of the report is to provide information:

- Which gives an overview of the Clinical Homecare Industry
- Which provides true Health Economics of current services
- Enable Health policy makers to understand the sector, in particular how the Homecare Sector can support key NHS and patient priorities
- Summary of how the Industry is funded, % NHS vs Pharmaceutical Manufacturers
- Evaluate the wider social economic impact of people continuing to work whilst on a homecare service
- Enable Patient / Clinician feedback from existing service users to be understood

10

Steering group

Mark Hackett, EX-CEO of Swansea Bay NHS Health Board and author of 'Vision for Future of Homecare Medicines' (2011)

Stephen Cook, Chief Pharmacist, Medway NHS Foundation Trust

Sharon Petford, Former Chair of the Royal College of Nursing Rheumatology Nursing Forum

Andrew Wilson, Head of NHS East Midlands Pharmacy Collaborative

Liz Lazenby, Head of Strategic Category Management Medicines and Homecare at NHS England

Richard Chapple, Homecare Services Manager at Royal Papworth Hospital NHS Foundation Trust

NCHA Board Members:
Stephanie Westwood, Alison Davis, Adrian Wilkinson, Brian Duggan

Special acknowledgments to **Wing Tang**, Head of Professional Standards at the Royal Pharmaceutical Society, and the Royal Pharmaceutical Society for their review of specific sections of the report, ensuring accuracy and alignment with RPS policy and standards.



11

With Independent Experts

Ed Grunill Senior Account Director at ZPB Associates

Tom Michaelis Senior Analyst at Edge Health

Stefania Deligia Lead Data Engineer at Edge Health

12

"I hope this report will be a rallying call to the parties involved. If we can bring together the NHS, the pharmaceutical industry, Clinical Homecare providers, and patients, united around a shared understanding and strategic view, then the opportunity is significant."

Mark Hackett, EX-CEO of Swansea Bay NHS Health Board and author of 'Vision for Future of Homecare Medicines' (2011)

13

Articulating value Through outcomes

14

Data and modelling

15

Study overview

Key elements of our economic model

- Defined and compared patient pathways
- Identified 11 economically quantifiable benefits
- Perspective of key NHS policy makers
- Benefits reported in monetary terms at an overall, and granular level

16

Modelling Methodology

Understanding the Approach



17



18



19



20

Patient survey:

We wanted the experience of patients to be central to the report. We achieved this through an objective and anonymous patient survey.

- **804 people surveyed**
- **404 have received Clinical Homecare in the last 12 months**
- **All nations represented**
- **Mix of backgrounds and therapeutic areas**
- **Anonymous and online**

21

The experience of Clinical Homecare

	Receiving Clinical Homecare	Receiving care in another setting
A positive impact on health	79%	36%
A positive impact on recovery	72%	41%
A positive impact on relationships	64%	27%
A positive impact on ability to work	58%	26%
A positive impact on ability to get on with life	75%	39%

22

Cost-benefit breakdown

An example of analysis

Reduced patient journey time

Clinical Homecare offers drug delivery directly to patient's homes. As a result, patients no longer need to travel to hospitals to collect each repeated prescription.



1. https://www.researchgate.net/publication/4708633_Distance_Travelled_in_the_NHS_in_England_for_Inpatient_Treatment
2. https://www.gov.uk/government/statistics/travel-time-measures-for-the-strategic-road-network-and-local-a-roads-january-to-december-2021
3. https://researchbriefings.files.parliament.uk/documents/CBP-8912/CBP-8912.pdf
4. https://www.nimblefins.co.uk/largest-car-insurance-companies/average-cost-petrol-car
5. https://webarchive.nationalarchives.gov.uk/ukgwa/20230602041648/ https://www.gov.uk/government/publications/
6. https://www.gov.uk/government/news/2-bus-fare-cap-across-england-to-save-passengers-money

23

£82m
To patients

£131m
In savings to the NHS

£50m
To society

£264m
Overall (to health economy)

24


Recommendations

25


1
Increased transparency from all parties, supported by better sharing of performance data with regular, robust and meaningful patient engagement.
2
Implementation of strategic leadership of Clinical Homecare at a national and regional level alongside improved regulation.
3
A review of contracting and commissioning regimes to support sustainable long-term planning.
4
Dedicated resources and funding made available in the NHS for the planning, contracting and commissioning of Clinical Homecare.
5
Increased standardisation across the industry, supported by expanded use of technology.

26


BEST KEPT SECRET: THE VALUE OF CLINICAL HOMECARE TO THE NHS, PATIENTS AND SOCIETY
62%
of people receiving Clinical Homecare reported that it has allowed them to stay in work or education.
75,000
Clinical Homecare patients avoid a 40-mile round trip with each delivery, mitigating geographical inequalities and burden.
£264m
represents the annual value delivered to UK health economy - delivered through operational savings, enhanced patient experience, and societal benefits.
85%
of Clinical Homecare patients are more likely to report that their medicines were fully explained to them, compared to the national average of 62%.
15 NHS
Trusts worth of day case elective capacity is delivered each year by Clinical Homecare companies.

27


Thank you – Copies of the Report are available today and from NCHA website
https://www.clinicalhomecare.org/bestkeptsecret/

28